EUVIMEDEUVIMED entdecken
Kohortenstudie

Sonographic Evolution and Pathologic Findings of Papillary Thyroid Cancer After Radiofrequency Ablation: A Five-Year Retrospective Cohort Study

Xinyang Li iD, Yingying Li, Lin Yan, Jing Xiao, Zhen Yang, Haoyu Jing, Mingbo Zhang, Yukun Luo

Thyroid® · 2024

DOI: 10.1089/thy.2023.0415 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Thyroid®, 2024. Verfasst von Xinyang Li und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ultrasound, The First Medical Center of Chinese PLA General Hospital, Beijing, China. Hauptthemen laut MEDLINE: Thyroid Neoplasms, Carcinoma, Papillary, Radiofrequency Ablation. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 36 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The criteria for determining technical efficacy of thermal ablation for papillary thyroid carcinoma (PTC) are not clearly defined. We analyzed the involution process of the ablation zone with clear pathologic results on core-needle biopsy (CNB) to clarify the relationship between sonographic changes and pathologic findings.

Methods

This retrospective cohort study included 382 patients with unifocal T1N0M0 PTC who underwent radiofrequency ablation (RFA) between May 2014 and August 2021. Patients with a single ablation zone biopsy (recommended at 3 or 6 months for T1a and 6 or 12 months for T1b) and regular neck ultrasound (US)/contrast-enhanced ultrasound imaging follow-up at 1, 3, 6, and 12 months and every 6–12 months thereafter after RFA were included. Patients also underwent yearly chest computed tomography. CNB was performed in the target lesion ablation zone's central, peripheral, and surrounding thyroid parenchyma to detect the presence of tumor cells. If the thyrotropin (TSH) was >2 mU/L, levothyroxine was prescribed with the intention of keeping the TSH 0.5–2 mU/L. Technical efficacy was defined as tumor disappearance by imaging follow-up together with the pathologically confirmed absence of tumor cells in the ablation zone.

Results

During the mean follow-up period of 67.8 ± 18.2 months (22–110 months), the overall incidence of persistent disease and the technical efficacy rate were 3.9% (15/382; 2.9% of T1a, and 12.2% of T1b) and 96.1%, respectively. Tumor size ( p = 0.03) and subcapsular location ( p = 0.04) were risk factors associated with persistent disease. The technical success rate was 100%. Of the 367 ablation zones with benign CNB results, 336 (91.6%) showed tumor disappearance on US and no re-emergence of imaging-visible tumors during follow-up. Male sex ( p = 0.006), age

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Thyroid NeoplasmsCarcinoma, PapillaryRadiofrequency AblationHumansMaleAdultThyroid Cancer, PapillaryRetrospective StudiesUltrasonographyTreatment OutcomeThyrotropin

Stichwörter der Autor:innen

core-needle biopsyinvolution of the ablation zonepapillary thyroid carcinomathermal ablationultrasound

Substanzen

Thyrotropin

Autor:innen und Institutionen

  • Department of Ultrasound, The First Medical Center of Chinese PLA General Hospital, Beijing, China.
  • School of Medicine, Nankai University, Tianjin, China.

ORCID-Profile: Xinyang Li

Zitieren

APA

Li, X., Li, Y., Yan, L., Xiao, J., Yang, Z., Jing, H., Zhang, M., & Luo, Y. (2024). Sonographic Evolution and Pathologic Findings of Papillary Thyroid Cancer After Radiofrequency Ablation: A Five-Year Retrospective Cohort Study. Thyroid®. https://doi.org/10.1089/thy.2023.0415

Vancouver

Li X, Li Y, Yan L, Xiao J, Yang Z, Jing H, et al. Sonographic Evolution and Pathologic Findings of Papillary Thyroid Cancer After Radiofrequency Ablation: A Five-Year Retrospective Cohort Study. Thyroid®. 2024. doi:10.1089/thy.2023.0415

BibTeX
@article{Li2024,
  author = {Li, Xinyang and Li, Yingying and Yan, Lin and Xiao, Jing and Yang, Zhen and Jing, Haoyu and Zhang, Mingbo and Luo, Yukun},
  title = {Sonographic Evolution and Pathologic Findings of Papillary Thyroid Cancer After Radiofrequency Ablation: A Five-Year Retrospective Cohort Study},
  journal = {Thyroid®},
  year = {2024},
  doi = {10.1089/thy.2023.0415}
}
Kostenlos starten →